Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.25
+2.31 (+2.85%)
Streaming Delayed Price
Updated: 2:16 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Today 13:46 EDT
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by...
Via
Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
Today 11:34 EDT
The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
What the Options Market Tells Us About Gilead Sciences
Today 11:02 EDT
Via
Benzinga
Four Stocks To Watch This Week - Monday, Sept 9
September 09, 2024
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels.
Via
Talk Markets
Peering Into Gilead Sciences's Recent Short Interest
September 06, 2024
Via
Benzinga
Unveiling 10 Analyst Insights On Gilead Sciences
September 04, 2024
Via
Benzinga
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
September 03, 2024
Via
Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
August 27, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
August 22, 2024
Via
Benzinga
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
September 03, 2024
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals.
Via
Benzinga
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
August 26, 2024
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.
Via
Investor's Business Daily
Exposures
Product Safety
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Peering Into Gilead Sciences's Recent Short Interest
August 20, 2024
Via
Benzinga
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
August 15, 2024
Via
Benzinga
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
August 08, 2024
The company retained its full-year outlook for product sales.
Via
Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
August 06, 2024
Via
Benzinga
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
August 16, 2024
Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs, intensifying its...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
August 15, 2024
FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued...
Via
Benzinga
Exposures
Product Safety
7 Defensive Stocks to Buy as Investors Seek Shelter
August 14, 2024
With the market primed for more jitters, investors should consider battening down the hatches with these defensive stocks.
Via
InvestorPlace
3 Stocks Retirees Should Absolutely Love
August 10, 2024
All of these stocks can provide steady income to retired investors.
Via
The Motley Fool
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
August 09, 2024
Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, and Oncology. Adjusted EPS surged to $2.01, surpassing estimates, supported by...
Via
Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
August 09, 2024
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic...
Via
Benzinga
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
August 08, 2024
GILD earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
August 08, 2024
U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
August 08, 2024
Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the...
Via
Benzinga
Four Stocks To Watch This Week - Monday, August 5
August 05, 2024
The unease we've been mentioning over the past several weeks has borne bearish fruit in the last two weeks. The good news is that stocks are correcting across the board, which means they will...
Via
Talk Markets
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
August 03, 2024
Dividend stocks are great; cheap dividend stocks are better.
Via
The Motley Fool
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
August 02, 2024
Traders are rushing out of overvalued and overhyped Nasdaq stocks, making it a great time to rotate into these Nasdaq stocks to watch.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.